Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) Research & Development: 2015-2024

Historic Research & Development for Intellia Therapeutics (NTLA) over the last 10 years, with Dec 2024 value amounting to $466.3 million.

  • Intellia Therapeutics' Research & Development fell 23.21% to $94.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $417.1 million, marking a year-over-year decrease of 9.02%. This contributed to the annual value of $466.3 million for FY2024, which is 7.18% up from last year.
  • Per Intellia Therapeutics' latest filing, its Research & Development stood at $466.3 million for FY2024, which was up 7.18% from $435.1 million recorded in FY2023.
  • Intellia Therapeutics' Research & Development's 5-year high stood at $466.3 million during FY2024, with a 5-year trough of $150.4 million in FY2020.
  • Over the past 3 years, Intellia Therapeutics' median Research & Development value was $435.1 million (recorded in 2023), while the average stood at $440.5 million.
  • Data for Intellia Therapeutics' Research & Development shows a peak YoY surged of 82.75% (in 2022) over the last 5 years.
  • Yearly analysis of 5 years shows Intellia Therapeutics' Research & Development stood at $150.4 million in 2020, then spiked by 52.79% to $229.8 million in 2021, then skyrocketed by 82.75% to $420.0 million in 2022, then rose by 3.59% to $435.1 million in 2023, then increased by 7.18% to $466.3 million in 2024.